Literature DB >> 7542009

The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity.

D T Fearon1, R H Carter.   

Abstract

B lymphocytes must respond to low concentrations of antigen despite having low affinity antigen receptors during the primary immune response. CD19, a B cell-restricted membrane protein of the immunoglobulin superfamily that associates with the antigen receptor complex, may help the B cell meet this requirement. Cross-linking CD19 to membrane immunoglobulin (mIg) lowers, by two orders of magnitude, the number of mIg that must be ligated to activate phospholipase C (PLC) or to induce DNA synthesis. CD19 is coupled, via protein tyrosine kinases (PTKs), to PLC and phosphatidylinositol 3' kinase (PI3' kinase), and it interacts with the Src-type nonreceptor PTK lyn. It also associates with two other membrane proteins, CR2 (complement receptor type 2, CD21), which permits nonimmunologic ligation of CD19, and TAPA-1, a member of the tetraspan family of membrane proteins. CR2 binds fragments of C3 that are covalently attached to glycoconjugates. This indirectly enables CD19 to be cross-linked to mIg after preimmune recognition of an immunogen by the complement system. CR2 also can be ligated by CD23, a lectin-like membrane protein that resides on cells that may present antigen to B cells. TAPA-1 associates with several other membrane proteins on B and T cells, including MHC class II, CD4, and CD8, and it promotes Ca2(+)- and LFA-1-independent homotypic aggregation when ligated directly or indirectly through CD19 or CR2. This may facilitate interaction of the B cell with other cells essential for cellular activation. The formation of this membrane protein complex by representatives of three different protein families helps the B cell resolve its dilemma of combining broad specificity with high sensitivity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542009     DOI: 10.1146/annurev.iy.13.040195.001015

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  107 in total

Review 1.  Do self-perpetuating B lymphocytes drive human autoimmune disease?

Authors:  J C Edwards; G Cambridge; V M Abrahams
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

2.  B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals.

Authors:  F Loder; B Mutschler; R J Ray; C J Paige; P Sideras; R Torres; M C Lamers; R Carsetti
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

3.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

Authors:  T M Ross; Y Xu; R A Bright; H L Robinson
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

4.  Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes.

Authors:  H Illges; M Braun; H H Peter; I Melchers
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 5.  Fortifying B cells with CD154: an engaging tale of many hues.

Authors:  J Gordon; J D Pound
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

6.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.

Authors:  T M Ross; Y Xu; T D Green; D C Montefiori; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

Review 7.  Studies of the humoral immune response.

Authors:  G Kelsoe
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

8.  EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells.

Authors:  Stéphanie Charrin; François Le Naour; Valérie Labas; Martine Billard; Jean-Pierre Le Caer; Jean-François Emile; Marie-Anne Petit; Claude Boucheix; Eric Rubinstein
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

Review 9.  Role of CD19 signal transduction in B cell biology.

Authors:  Robert H Carter; Yue Wang; Stephen Brooks
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 10.  Complement in the immunopathogenesis of rheumatic disease.

Authors:  Gunnar Sturfelt; Lennart Truedsson
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.